Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Kurt A. Jaeckle, S. K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Brian Jenkins, Merrill J. Egorin, Jann N Sarkaria, Paul D. Brown, P. J. Flynn, John Schwerkoske, Jan Craig Buckner, Evanthia Galanis

Research output: Contribution to journalComment/debate

Abstract

The last author's first name was truncated in the initial online publication. The original article has been corrected.

Original languageEnglish (US)
Number of pages1
JournalJournal of neuro-oncology
Volume143
Issue number3
DOIs
StatePublished - Jul 1 2019

Fingerprint

Oligodendroglioma
Astrocytoma
Names
Publications
Neoplasms
Imatinib Mesylate

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

@article{0adaf13857ae4b32bf4b985e2682fb6f,
title = "Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)",
abstract = "The last author's first name was truncated in the initial online publication. The original article has been corrected.",
author = "Jaeckle, {Kurt A.} and Anderson, {S. K.} and Twohy, {Erin L.} and Dixon, {Jesse G.} and Caterina Giannini and Jenkins, {Robert Brian} and Egorin, {Merrill J.} and Sarkaria, {Jann N} and Brown, {Paul D.} and Flynn, {P. J.} and John Schwerkoske and Buckner, {Jan Craig} and Evanthia Galanis",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s11060-019-03201-3",
language = "English (US)",
volume = "143",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Correction to

T2 - Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

AU - Jaeckle, Kurt A.

AU - Anderson, S. K.

AU - Twohy, Erin L.

AU - Dixon, Jesse G.

AU - Giannini, Caterina

AU - Jenkins, Robert Brian

AU - Egorin, Merrill J.

AU - Sarkaria, Jann N

AU - Brown, Paul D.

AU - Flynn, P. J.

AU - Schwerkoske, John

AU - Buckner, Jan Craig

AU - Galanis, Evanthia

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The last author's first name was truncated in the initial online publication. The original article has been corrected.

AB - The last author's first name was truncated in the initial online publication. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85067028011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067028011&partnerID=8YFLogxK

U2 - 10.1007/s11060-019-03201-3

DO - 10.1007/s11060-019-03201-3

M3 - Comment/debate

C2 - 31165953

AN - SCOPUS:85067028011

VL - 143

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -